GRIFOLS, S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.46 USD | +3.80% |
|
+6.64% | -37.24% |
| 15/05 | GRIFOLS : In line Q1 and on track deleveraging; worth a go |  |
| 14/05 | Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -37.24% | 6.63B | - | ||
| +0.10% | 91.42B | A- | ||
| +2.76% | 41.08B | A- | ||
| -11.40% | 34.26B | B- | ||
| +54.06% | 25.27B | A | ||
| -9.87% | 12.81B | B- | ||
| -12.11% | 11.6B | D+ | ||
| -43.61% | 11.42B | B | ||
| +5.39% | 9.16B | B+ | ||
| -6.90% | 8.22B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GRF Stock
- GIKLY Stock
- Ratings Grifols, S.A.
